"Turpentine VC" | Venture Capital and Investing

E52: Charting the Course of Biotech with Laura Deming, GP of Longevity Fund, and Will Eden of Sylvan Consulting

Aug 20, 2024
Laura Deming, a General Partner at Longevity Fund, and Will Eden from Sylvan Consulting delve into the fascinating world of biotech investments. They explore the evolution of longevity research and groundbreaking technologies like cell and gene therapies. The duo discusses the FDA's complex role in regulating innovations and the challenges faced by biotech startups. They also highlight the dramatic growth in the longevity sector since 2011 and ponder bold aspirations like biological immortality, making the conversation both insightful and entertaining.
Ask episode
Chapters
Transcript
Episode notes